AbbVie, Inc. ABBVannounced that the FDA has granted approval for the combination use of its cancer drug Venclexta and Roche’s RHHBYRituxan for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (“CLL”) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.
Abbvie/Roche's Leukemia Drugs Combination Gets FDA Approval
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться